Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
13.12
-0.13 (-0.98%)
May 9, 2025, 11:29 AM - Market open
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 609 employees as of September 30, 2024. The number of employees increased by 84 or 16.00% compared to the previous year.
Employees
609
Change (1Y)
84
Growth (1Y)
16.00%
Revenue / Employee
$4,105
Profits / Employee
-$1,050,433
Market Cap
1.65B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
| Eli Lilly and Company | 47,000 |
ARWR News
- 2 days ago - Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences - Business Wire
- 8 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results - Business Wire
- 23 days ago - Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Arrowhead Pharmaceuticals Is Finally Arriving - Seeking Alpha
- 2 months ago - Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Business Wire